Has the Expert Committee of the Food and Drug Administration unanimously approved Eli Lilly's new drug? Will Alzheimer's patients have new choices?
楚一帆
发表于 2024-6-11 17:23:42
224
0
0
On June 10th, Lilly's Alzheimer's disease (AD) drug Donanemab was unanimously approved by the FDA's Advisory Committee on Peripheral and Central Nervous System Drugs (PCNS).
CandyLake.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
转播
猜你喜欢
- Has the era of AI's iPhone begun? Altman targets AI hardware with a single image to understand his billion dollar investment empire
- Don't just focus on the storm caused by the strong US dollar: Will these stocks have opportunities on a global scale?
- After Tesla's two major super factories land in Shanghai Lingang in five years, will there be a third one for vehicle and energy storage?
- Eli Lilly's new drug for Alzheimer's disease, Kisumla, has been approved by the US FDA
- The second Alzheimer's disease drug approved by the United States: Eli Lilly R&D, with an annual treatment cost of $32000
- Eli Lilly's new Alzheimer's disease drug Donanemab has been approved for pricing in Japan
- Eli Lilly's Alzheimer's disease therapy, Minolta (Donaimab Injection), has been approved in China
- Eli Lilly's Alzheimer's disease treatment with donentinumab injection approved
- Eli Lilly's Alzheimer's disease therapy, Minolta (Donaimab Injection), has been approved in China
- Eli Lilly's new Alzheimer's disease drug launched: annual drug cost exceeds $30000, Pfizer Roche is expanding its strategy
